NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Tuesday announced that its pneumonia vaccine Prevnar 13 has received U.S. Food and Drug Administration approval for an expanded age indication to include adults 18 through 49 years of age.
Prevnar 13 is the only pneumococcal vaccine approved across the lifespan.
'This expanded age indication in adults 18 to 49 offers an important public health benefit as appropriate vaccination against S. pneumoniae is critical to reducing the risk of pneumococcal disease, including in those with immunocompromising conditions,' said Dr. Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.
Copyright RTT News/dpa-AFX
© 2016 AFX News
